Business Wire

The Estée Lauder Companies Inc. Acquires By Kilian


The Estée Lauder Companies Inc. (NYSE:EL) announced today that it has acquired By Kilian, the Paris-based prestige fragrance brand that embodies timeless sophistication and modern luxury. Terms of the deal were not disclosed.

Founded in 2007 by Kilian Hennessy, By Kilian has built a passionate global following with its distinctive emphasis on sensuous olfactive storytelling. Sold in more than 40 countries worldwide – primarily in North America, Europe and the Middle East – through immersive freestanding stores, select prestige department stores and perfumeries, By Kilian offers an exclusive “wardrobe” of scents that reflect Mr. Hennessy’s deep-rooted legacy of luxury and creativity. By Kilian’s current product offerings include fragrances, candles and other accessories, as well as exclusive collections available in certain regions. Elements of the brand’s packaging – including perfume bottles and candle holders – are meant to be kept as keepsakes, which is reflective of Kilian’s philosophy that true luxury should not be disposable.

“By Kilian is a perfect complement to our portfolio of prestige fragrances,” said Fabrizio Freda, President and Chief Executive Officer of The Estée Lauder Companies Inc. “Kilian has built a beautiful and sumptuous brand that elevates the art of perfume creation with elegance and uncompromising luxury. This acquisition gives our Company a strategic opportunity to continue to build upon our leadership in ultra-luxury fragrances. We are very excited to work closely with Kilian and the entire By Kilian team to continue building on the brand’s terrific success.”

“I could not imagine a better home for my brand,” said By Kilian founder and CEO Kilian Hennessy. “The Estée Lauder Companies not only understands the philosophy behind By Kilian – which is to bring perfumery back to the level of luxury that it enjoyed in the early 20th century – but also has the resources and support to help By Kilian continue to strategically grow by category, region and distribution. The Company has an incredible track record of nurturing entrepreneurial brands, and I’m thrilled to be partnering with them.”

“Kilian’s heritage of sophistication and luxury is a terrific match for The Estée Lauder Companies,” said William P. Lauder, Executive Chairman, The Estée Lauder Companies Inc. “One of our leading strengths is the ability to identify brands with unique positioning and nurture them to realize their full growth potential. We are so pleased to partner with Kilian to continue this legacy, and we welcome him and his team to our family.”

John Demsey, Executive Group President, The Estée Lauder Companies Inc., will add By Kilian to his portfolio, while continuing to oversee Clinique, M·A·C Cosmetics, Tom Ford Beauty, Prescriptives, Bobbi Brown, Jo Malone London, Smashbox, Aramis & Designer Fragrances, the Men’s Skincare Group, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW.

In this transaction, BNP Paribas served as financial advisor to The Estée Lauder Companies Inc., while Lowenstein Sandler LLP, Wragge Lawrence Graham & Co. LLP and Arendt & Medernach served as legal counsel. By Kilian received financial advice from Michel Dyens & Co. and legal counsel from Skadden, Arps, Slate, Meagher and Flom LLP and CMS Bureau Francis Lefebvre.

The forward-looking statements in this press release, including those in the quoted remarks and those relating to the expectations for the acquired brand and the benefits of the acquisition, involve risks and uncertainties. Factors that could cause actual results to differ materially from those forward-looking statements include current economic and other conditions in the global marketplace, actions by retailers, suppliers and consumers, competition, the Company's ability to successfully integrate the acquired business and/or implement its long-term strategic plan, and those described in the Company's annual report on Form 10-K for the year ended June 30, 2015.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in over 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, Marni, Tory Burch, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW and By Kilian.

Contact information

The Estée Lauder Companies Inc.
Investor Relations:
Dennis D’Andrea, 212-572-4384
Media Relations:
Alexandra Trower, 212-572-4430

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on